Vonvendi is the only recombinant Von Willebrand factor replacement therapy with approved indications in adults and children with VWD
It will focus on interface between API and formulation manufacturing, reducing carbon footprint in formulation production, creating intellectual property, training next-generation scientists, and setting new industry benchmarks
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
Now integrates with Abbott’s instinct sensor and approved for type 2 diabetes
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
The updated formula for Spikevax is now approved for individuals 6 months through 64 years of age
VYVGART was well tolerated, with a safety profile consistent with prior studies in AChR-Ab seropositive gMG and other indications
This project shall be implemented through incorporation of a new joint venture company in Zambia
Vivo Bio Tech will have end-to-end responsibility for conducting the full spectrum of pre-clinical safety and regulatory studies
Subscribe To Our Newsletter & Stay Updated
